Connect Biopharma Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation

Reuters

2025/09/03

<a href="https://laohu8.com/S/CNTB">Connect Biopharma</a> Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation

Connect Biopharma Holdings Ltd. has released a corporate presentation detailing its recent advancements and strategic focus areas. The company is advancing its next-generation anti-interleukin-4-receptor alpha (IL-4Rα) treatment, Rademikibart, targeted at eosinophilic-driven respiratory diseases. Rademikibart is positioned as a promising option for the treatment of acute exacerbations in asthma and COPD, with market research highlighting its potential advantage over existing biologics like dupilumab. The company has initiated parallel Phase 2 studies for this purpose, with topline data expected in the first half of 2026. Connect Biopharma holds global development and commercialization rights for Rademikibart outside of greater China. The company anticipates significant commercial opportunities, with projected worldwide peak sales exceeding $3 billion for asthma and $2 billion for COPD. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2564339566"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564339566\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564339566?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-03 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564339566","market":"nz","top_or_hot":-1,"title":"Connect Biopharma Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CNTB\">Connect Biopharma</a> Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Connect Biopharma Holdings Ltd. has released a corporate presentation detailing its recent advancements and strategic focus areas. The company is advancing its next-generation anti-interleukin-4-receptor alpha (IL-4Rα) treatment, Rademikibart, targeted at eosinophilic-driven respiratory diseases. Rademikibart is positioned as a promising option for the treatment of acute exacerbations in asthma and COPD, with market research highlighting its potential advantage over existing biologics like dupilumab. The company has initiated parallel Phase 2 studies for this purpose, with topline data expected in the first half of 2026. Connect Biopharma holds global development and commercialization rights for Rademikibart outside of greater China. The company anticipates significant commercial opportunities, with projected worldwide peak sales exceeding $3 billion for asthma and $2 billion for COPD. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Connect Biopharma Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nConnect Biopharma Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-03 20:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CNTB\">Connect Biopharma</a> Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Connect Biopharma Holdings Ltd. has released a corporate presentation detailing its recent advancements and strategic focus areas. The company is advancing its next-generation anti-interleukin-4-receptor alpha (IL-4Rα) treatment, Rademikibart, targeted at eosinophilic-driven respiratory diseases. Rademikibart is positioned as a promising option for the treatment of acute exacerbations in asthma and COPD, with market research highlighting its potential advantage over existing biologics like dupilumab. The company has initiated parallel Phase 2 studies for this purpose, with topline data expected in the first half of 2026. Connect Biopharma holds global development and commercialization rights for Rademikibart outside of greater China. The company anticipates significant commercial opportunities, with projected worldwide peak sales exceeding $3 billion for asthma and $2 billion for COPD. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CNTB","symbol_name":"康乃德生物醫藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL4TYCX0:1","article_id":"2564339566","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564339566","pubTimestamp":1756903217,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Connect Biopharma Holdings Ltd. has released a corporate presentation detailing its recent advancements and strategic focus areas. The company is advancing its next-generation anti-interleukin-4-receptor alpha  treatment, Rademikibart, targeted at eosinophilic-driven respiratory diseases. Rademikibart is positioned as a promising option for the treatment of acute exacerbations in asthma and COPD, with market research highlighting its potential advantage over existing biologics like dupilumab. The company has initiated parallel Phase 2 studies for this purpose, with topline data expected in the first half of 2026. Connect Biopharma holds global development and commercialization rights for Rademikibart outside of greater China. The company anticipates significant commercial opportunities, with projected worldwide peak sales exceeding $3 billion for asthma and $2 billion for COPD. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CNTB":"康乃德生物医药","BK4139":"生物科技"},"translate_title":"Connect Biopharma在最新演示中展示了Rademikibart在哮喘和COPD治疗方面的巨大潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTB":0.9},"content_text":"Connect Biopharma Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation\n    \n\n        Connect Biopharma Holdings Ltd. has released a corporate presentation detailing its recent advancements and strategic focus areas. The company is advancing its next-generation anti-interleukin-4-receptor alpha (IL-4Rα) treatment, Rademikibart, targeted at eosinophilic-driven respiratory diseases. Rademikibart is positioned as a promising option for the treatment of acute exacerbations in asthma and COPD, with market research highlighting its potential advantage over existing biologics like dupilumab. The company has initiated parallel Phase 2 studies for this purpose, with topline data expected in the first half of 2026. Connect Biopharma holds global development and commercialization rights for Rademikibart outside of greater China. The company anticipates significant commercial opportunities, with projected worldwide peak sales exceeding $3 billion for asthma and $2 billion for COPD. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}